Page last updated: 2024-12-07

phenylalaninol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

phenylalaninol: inhibits intestinal absorption of phenylalanine; RN given refers to cpd with unspecified stereochemistry [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-phenylalaninol : An amino alcohol resulting from the formal reduction of the carboxy group of L-phenylalanine to the corresponding alcohol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID447213
CHEMBL ID1235287
CHEBI ID45086
SCHEMBL ID81769
MeSH IDM0059535

Synonyms (89)

Synonym
smr001306708
AC-5650
MLS002207066
BB 0262987
BRD-K44204252-001-02-2
CHEMBL1235287 ,
9ge9qop0et ,
unii-9ge9qop0et
l-2-amino-3-phenyl-1-propanol
benzenepropanol, beta-amino-, (s)-
s-phenylalaninol
1-propanol, 2-amino-3-phenyl-, l-
(s)-beta-aminobenzenepropanol
(s)-2-benzylethanolamine
einecs 221-674-4
l-2-amino-3-phenylpropan-1-ol
BSPBIO_003578
DB04484
l-phenylalaninol
(s)-(-)-2-amino-3-phenyl-1-propanol, 98%, optical purity ee: 99% (hplc)
KBIO3_002959
SPECTRUM3_001978
SPECTRUM2_000830
SPBIO_000759
SPECTRUM1505339
NCGC00177983-01
P-3550
(s)-phenylalaninol
(2s)-2-amino-3-phenylpropan-1-ol
(r)-(+)-2-amino-3-phenyl-1-propanol
l(-)-2-amino-3-phenyl-1-propanol
(l)-(-)-2-phenylalaninol
3182-95-4
(s)-(-)-2-amino-3-phenyl-1-propanol
P1028
phenylalaninol
AKOS005259774
(s)-2-amino-3-phenyl-1-propanol
l-(-)-phenylalaninol
CCG-40282
bdbm50367058
h-phenylalaninol
BP-20243
AM20040161
gtpl4752
SCHEMBL81769
l-phenylalanoil
2-amino-3-phenyl-1-propanol #
benzenepropanol, .beta.-amino-, (s)-
P-3551
(s)-2-amino-3-phenyl-propan-1-ol
(2s)-2-amino-3-phenyl-1-propanol
(1s)-1-benzyl-2-hydroxyethylamine
(s)(-)-2-amino-3-phenyl-1-propanol
(s)-1-hydroxymethyl-2-phenyl-ethylamine
(s)-(-)-2-arnino-3-phenyl-1-propanol
(l)-phenylalaninol
2-(s)-amino-3-phenyl-1-propanol
l-2-phenylalaninol
l-benzylglycinol
(s)-2-amino-3-phenylpropan-1-ol
h-phe-ol
l(-)-phenylalaninol
(s)-(-)-phenylalaninol
1-phenylalaninol
l-phenyl alaninol
(-)-l-phenylalaninol
l-(s)-phenylalaninol
(s)-(-)-2-amino-3-phenyl-propanol
TS-01999
AC-16295
AC-22383
mfcd00004732
benzenepropanol, .beta.-amino-, (.beta.s)-
d-(+)-2-amino-3-phenyl-1-propanol?
J-520201
Z1741982891
CS-D1142
bound form of phenylalaninal
BCP17030
Q27081711
BRD-K44204252-001-04-8
l-(-)-2-amino-3-phenyl-1-propanol
phenylalaninol, (s)-
(-)-2-amino-3-phenyl-1-propanol
CHEBI:45086
DTXSID001025528
EN300-91756
HY-Y0168
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
amino alcoholAn alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Smad3Homo sapiens (human)Potency5.62340.00527.809829.0929AID588855
gemininHomo sapiens (human)Potency0.51740.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phenylethanolamine N-methyltransferaseBos taurus (cattle)Ki664.00000.00312.329310.0000AID145544
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
methylationPhenylethanolamine N-methyltransferaseBos taurus (cattle)
epinephrine biosynthetic processPhenylethanolamine N-methyltransferaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
phenylethanolamine N-methyltransferase activityPhenylethanolamine N-methyltransferaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1148043Acute toxicity in CF1 mouse1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID145544Inhibitory activity against bovine adrenal norepinephrine N-methyl-transferase was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Probes of the active site of norepinephrine N-methyltransferase: effect of hydrophobic and hydrophilic interactions on side-chain binding of amphetamine and alpha-methylbenzylamine.
AID1148041Antitumor activity against mouse EAC allografted in CF1 mouse assessed as tumor volume at 33 mg/kg/day measured on day 71977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1148042Antitumor activity against mouse EAC allografted in CF1 mouse assessed as inhibition of tumor growth at 33 mg/kg/day measured on day 71977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (25.71)18.7374
1990's2 (5.71)18.2507
2000's5 (14.29)29.6817
2010's12 (34.29)24.3611
2020's7 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (97.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]